

Response

2
The Department may, at its discretion, publish part or all of the information provided in your submission on the Department's website or in related documents. If information from your submission is published, the Department may identify you and/or your organisation as the author of the submission. All personal contact details will be removed prior to publishing.
Yes, I consent to my identified submission being published

3
What is your name?
Rodney Pearce

7
Please select the type of individual(s) or organisation(s) you represent. Please select all that apply. - Selected Choice
Other [please specify]

7.22
Please select the type of individual(s) or organisation(s) you represent. Please select all that apply. - Other [please specify] - Text
Independent , not for profit immunisation advocacy group

8.1
What is the name of your organisation? - My organisation is called: - Text
immunisation Coalition

9
Are you making feedback on behalf of your organisation?
Your organisation

13
Please select which chapter/s you would like to provide feedback on. You may provide feedback on as many or few chapters as you wish.
1. Transparency, communication, and stakeholder involvement in HTA,2. Health technology funding and assessment pathways,3. Methods for HTA for Australian government subsidy (technical methods),4. Health technology funding and purchasing approaches and managing uncertainty,5. Futureproofing Australia's systems and processes

14
Please select the topics within the chapter(s) you would like to provide feedback on. 1. Transparency, communication and stakeholder involvement in HTA
1.1. Transparency and communication of HTA pathways, processes and decisions,1.2. Consumer, clinician and other stakeholder engagement and consideration in HTA,1.3. First Nations people involvement and consideration in HTA,1.4. State and territory government collaboration in HTA

15
Please select the topics within the chapter(s) you would like to provide feedback on. 2. Health technology funding and assessment pathways
2.1. Streamlining and aligning HTA pathways and advisory committees,2.2. Proportionate appraisal pathways

16
Please select the topics within the chapter(s) you would like to provide feedback on. 3. Methods for HTA for Australian government subsidy (technical methods)
3.1. Determination of the Population, Intervention, Comparator, Outcome,3.2. Clinical Evaluation Methods,3.3. Economic evaluation

17
Please select the topics within the chapter(s) you would like to provide feedback on. 4. Health Technology funding and purchasing mechanisms and decisions
4.1. Approaches to funding or purchasing new health technologies,4.2. Approaches to incentivise development of products that address antimicrobial resistance (AMR),4.3. Understanding the performance of health technologies in practice

18
Please select the topics within the chapter(s) you would like to provide feedback on. 5. Futureproofing our systems and processes
5.1. Proactively addressing areas of unmet clinical need and gaps in the PBS,5.2. Establishment of horizon scanning programs to address specific informational needs within HTA and the health system,5.3. Consideration of environmental impacts in the HTA,5.4. Mechanisms for continuous review and improvement,5.5. Capacity and capability of the HTA system,5.6. Strengthen international partnerships and work-sharing

23.1
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Publish plain language summaries
Very positive

23.2
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Improvements to the HTA webpage including development of a dashboard
Positive

27
Taking all Options within this section: 1.2. Consumer, clinician and other stakeholder engagement and consideration in HTA into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?
Completely address the issue(s)

28
If you would like to expand on your answer above you can do so below:
Need third party consultation. primary care and front line workers need to be more involved because they need to deliver the programs. They need to be able to trust the advice and sources and there needs to be transparency

29.1
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Develop an engagement framework
Very positive

29.2
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Strengthen consumer evidence
Neutral

31
If you would like to expand on your answer above you can do so below -Develop an engagement framework
Consultation with all the stakeholders from government to consumer. Note the importance of WHO, Government (all levels include local gov.) pharmacy, mobile work place vax, GPs , wholesalers-supply chain, nurses

33
Taking all Options within this section: 1.3. First Nations people involvement and consideration in HTA into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?
Address some but not most of the issue(s)

34
If you would like to expand on your answer above you can do so below:
Need to be in the consultation process for all providers to see

35.1
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - First Nations peoples partnership in decision making
Neutral

35.2
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Dedicated resource for HTA submissions and education
Neutral

39
Taking all Options within this section: 1.4. State and territory government collaboration in HTA into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?
Mostly address the issue(s)

40
If you would like to expand on your answer above you can do so below:
States are not cooperating with the Australian government , if so not apparent. The roll out of programs is diminished through federal program being different in each state, yet the vaccine providers get their information from either state or federal, often conflicting
Consumers then lose confidence because they see "bickering" and conflicts

41.1
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Development of central standardised data sharing system for utilisation and outcome data
Very positive

41.2
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Increase opportunities for consultation and work sharing
Very positive

41.3
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Health technologies that are jointly funded by the Commonwealth and state and territory governments (such as high cost, Highly Specialised Therapies (HSTs) delivered to public hospital inpatients)
Neutral

45
If you would like to expand on your answer above you can do so below -Health technologies that are jointly funded by the Commonwealth and state and territory governments (such as high cost, Highly Specialised Therapies (HSTs) delivered to public hospital inpatients)
Most of the work is NOT about the public hospital system

46
Taking all Options within this section: 2.1. Streamlining and aligning HTA pathways and advisory committees into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?
Address little or none of the issue(s)

47
If you would like to expand on your answer above you can do so below:
Vaccines need specific advice outside of the PBAC process and needs to stay outside of the assessment or independent. ATAGI's role is not just to advise PBAC

48.1
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Pathway for drugs for ultra-rare diseases (Life Saving Drugs Program (LSDP))
Very negative

48.2
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Vaccine pathway
Very negative

48.3
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Expanding role of PBAC
Very negative

48.4
If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Unified HTA pathway for all health technologies with Commonwealth funding

Don't know

60

If you would like to expand on your answer above you can do so below -Vaccine pathway

ATAGI has been the go to place for vaccines. Best use of medicines is about best use of vaccines. Separate and supporting PBAC maybe but beholden to PBAC processes

Clinicians need clinical advice not program advice from ATAGI

Any advice to PPAC cant be at the cost of deminishing the historic and valued place of ATAGI

61

If you would like to expand on your answer above you can do so below -Expanding role of PBAC

Not to subsume vaccine. Vaccine need to be assessed differently from other medication and Australia risks loosing the true value and investment in vaccination programs if run by PBC

63

Taking all Options within this section: 2.2. Proportionate appraisal pathways into account

Overall, to what extent could the options (if implemented) address the issues that relate to them?

Address little or none of the issue(s)

64

If you would like to expand on your answers above you can do so below:

vaccines and drugs should be looked at differently. Horizon scanning and the place of vaccine now and the future have to be valued differently and anticipated because of their wide ranging impact and need to be delivered confidently

65.1

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Case manager

Very negative

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Triaging submissions

Positive

65.2

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Streamlined pathway for cost-minimisation submissions (therapies not claiming a significant improvement in health outcomes or reduction in toxicity)

Very negative

65.3

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN:

Alternative option 1: Introducing an optional resolution step before HTA committee consideration

Very negative

65.4

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Early resolution mechanisms for submissions of major new therapeutic advances in areas of HUCN:

Alternative option 2: Introducing an optional resolution step before HTA committee consideration, with additional post committee resolution

Very negative

65.5